CD19 and acute lymphoblastic leukemia: We report the case of a 30-year-old female patient with relapsed B-cell acute lymphoblastic leukemia (B-ALL) who developed grade 3 ICANS and hemodynamic instability following treatment with a de-intensified dose of brexucabtagene autoleucel, an anti-CD19 CAR-T product.